%0 Journal Article
%A Bastos-Oreiro, Mariana
%A Gutierrez, Antonio
%A Reguera, Juan Luís
%A Iacoboni, Gloria
%A López-Corral, Lucía
%A Terol, María José
%A Ortíz-Maldonado, Valentín
%A Sanz, Jaime
%A Guerra-Dominguez, Luisa
%A Bailen, Rebeca
%A Mussetti, Alberto
%A Abrisqueta, Pau
%A Hernani, Rafael
%A Luzardo, Hugo
%A Sancho, Juan-Manuel
%A Delgado-Serrano, Javier
%A Salar, Antonio
%A Grande, Carlos
%A Bento, Leyre
%A González de Villambrosía, Sonia
%A García-Belmonte, Daniel
%A Sureda, Anna
%A Pérez-Martínez, Antonio
%A Barba, Pere
%A Kwon, Mi
%A Martín García-Sancho, Alejandro
%T Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.
%D 2022
%U http://hdl.handle.net/10668/20580
%X Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated with commercial CAR T-cell therapy in Spain (204 patients included and 192 treated, 101 with axicabtagene ciloleucel [axi-cel], and 91 with tisagenlecleucel [tisa-cel]) and compared the results with a historical refractory population of patients (n = 81) obtained from the GELTAMO-IPI study. We observed superior efficacy for CAR-T therapy (for both axi-cel and tisa-cel) over pSOC, with longer progression-free survival (PFS) (median of 5.6 vs. 4-6 months, p ≤ 0.001) and overall survival (OS) (median of 15 vs. 8 months, p
%K CAR-T cell therapy
%K real world evidence (RWE)
%K refractory aggressive B cell lymphoma
%K scholar-1 criteria
%K standard of care (SOC)
%~